Eli Lilly Ends Coronavirus Antibody Treatment Trial, Other Studies Go On

In this May 2020 file image provided by Eli Lilly, a scientist tests possible COVID-19 antibodies in a lab in Indianapolis. On Monday, U.S. government authorities revealed they are putting an early end to a study checking an Eli Lilly antibody drug for individuals hospitalized with COVID-19 since it does not appear to assist.

David Morrison/AP

hide caption

toggle caption

David Morrison/AP

In this May 2020 file image offered by Eli Lilly, a researcher tests possible COVID-19 antibodies in a lab in Indianapolis. On Monday, U.S. federal government officials revealed they are putting an early end to a study testing an Eli Lilly antibody drug for people hospitalized with COVID-19 because it doesnt appear to help.

David Morrison/AP

The decision to end this particular research study does not put an end to Lillys investment in the speculative therapy. Business authorities stated they “remain positive … that bamlanivimab monotherapy may prevent progression of illness for those earlier in the course of COVID-19.”

The research study of the monoclonal antibody called bamlanivimab was at first paused by the company on Oct. 13 out of “an abundance of care,” due to the fact that of a prospective security concern. For this particular research study the treatment was being used in mix with remdesivir, an antiviral with emergency situation use permission for the infection.

But on Monday, the National Institutes of Health, which sponsored the trial, found the drug presented no significant security threats for clients. Instead, scientists said, “bamlanivimab is unlikely to help hospitalized COVID-19 patients recuperate from this sophisticated stage of their illness.”

That is the exact same compound treatment President Trump received after contracting the coronavirus.

The company and the NIH are pursuing several additional trials including the antibody, which is designed to stop the infection from contaminating cells. All target patients in less advanced phases of the disease.

Eli Lilly & & Co. is ending a scientific trial of its antibody drug in hospitalized COVID-19 clients after federal scientists concluded the therapy does not deal with them.